middle.news
How Will Tetratherix’s $25M IPO and Bio Optix Deal Reshape Ophthalmic Care?
8:55am on Wednesday 23rd of July, 2025 AEST
•
Healthcare
Read Story
How Will Tetratherix’s $25M IPO and Bio Optix Deal Reshape Ophthalmic Care?
8:55am on Wednesday 23rd of July, 2025 AEST
Key Points
Exclusive strategic licensing agreement signed with Bio Optix Inc.
Successful ASX listing raising $25 million with no debt
Completion of FDA pre-submission meeting for Tutelix prostate spacer
Strong cash position of AUD 29.3 million to fund R&D and manufacturing expansion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Tetratherix (ASX:TTX)
OPEN ARTICLE